Céline Robert-Tissot

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 739 citations

Life Sciences, Immunology, Oncology +14

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Howard A. Burris, Manish R. Patel, Daniel C. Cho et al. · Journal of Clinical Oncology · 2019 · 144 citations

Life Sciences, Immunology, Oncology +17

Coenzyme A fuels T cell anti-tumor immunity

Michael St. Paul, Samuel D. Saibil, SeongJun Han et al. · Cell Metabolism · 2021 · 106 citations · Full text

Life Sciences, Cancer Biology, Immunology +10

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Justin F. Gainor, Manish R. Patel, Jeffrey S. Weber et al. · Cancer Discovery · 2024 · 100 citations

Medicine, Immunology, Oncology +17

IRF4 and BATF are critical for CD8+ T-cell function following infection with LCMV

Melanie Grusdat, David R. McIlwain, Haifeng C. Xu et al. · Cell Death and Differentiation · 2014 · 91 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17